US 12,066,443 B2
Method of treating acute coronary syndrome
Anthony Dart, Melbourne (AU); and Wei Gao, Beijing (CN)
Assigned to Alfred Health, Melbourne (AU); and Peking University Third Hospital, Beijing (CN)
Appl. No. 16/651,860
Filed by ALFRED HEALTH, Melbourne (AU); and PEKING UNIVERSITY THIRD HOSPITAL, Beijing (CN)
PCT Filed Sep. 27, 2018, PCT No. PCT/AU2018/051059
§ 371(c)(1), (2) Date Mar. 27, 2020,
PCT Pub. No. WO2019/060960, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. PCT/CN2017/104752 (WO), filed on Sep. 30, 2017.
Prior Publication US 2020/0256878 A1, Aug. 13, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); A61B 5/00 (2006.01); A61B 5/02 (2006.01); G16H 10/40 (2018.01); G16H 40/63 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01); G16H 70/60 (2018.01)
CPC G01N 33/6893 (2013.01) [A61B 5/02 (2013.01); A61B 5/7275 (2013.01); G16H 10/40 (2018.01); G16H 40/63 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/70 (2018.01); G16H 70/60 (2018.01); G01N 2333/4712 (2013.01); G01N 2333/52 (2013.01); G01N 2333/58 (2013.01); G01N 2800/324 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01)] 14 Claims
 
1. A method of treating acute coronary syndrome (ACS) in a subject, the method comprising:
determining the concentration of:
(a) macrophage migration inhibitory factor (MIF), and
(b) N-terminal prohormone of brain natriuretic peptide (Nt-proBNP), or brain natriuretic peptide (BNP),
in a sample from the subject, wherein the sample is blood, plasma or serum,
comparing the concentration of MIF to a reference MIF concentration, wherein the reference MIF concentration is at least 70 ng/ml,
comparing the concentration of Nt-proBNP (or BNP) to a reference Nt-proBNP (or BNP) concentration, wherein the reference Nt-proBNP (or BNP) concentration is at least 700 pg/mL, and
performing percutaneous coronary intervention (PCI) and/or fibrinolysis on the subject when the concentrations of MIF and Nt-proBNP (or BNP) from the sample are equal to or higher than the reference concentrations of MIF and Nt-proBNP (or BNP),
thereby treating the subject having ACS.